Holen Sie sich die Stockscreener-App
0.95
3.73%
-0.0368
Handel nachbörslich:
.97
0.02
+2.11%
Lucid Diagnostics Inc Aktie (LUCD) Neueste Nachrichten
Lucid Diagnostics to Present at Canaccord Genuity Healthcare Forum | PAVM Stock News - StockTitan
LUCDLucid Diagnostics Inc. Latest Stock News & Market Updates - StockTitan
Cantor Fitzgerald cuts Lucid Diagnostics stock target, overweight on challenges - Investing.com India
Lucid Diagnostics (NASDAQ:LUCD) Price Target Lowered to $2.00 at Cantor Fitzgerald - MarketBeat
Lucid Diagnostics (NASDAQ:LUCD) Provides Business Update and Financial Results - Defense World
Lucid Diagnostics' (LUCD) Buy Rating Reiterated at Canaccord Genuity Group - MarketBeat
Needham & Company LLC Reaffirms "Buy" Rating for Lucid Diagnostics (NASDAQ:LUCD) - MarketBeat
PAVmed Inc Reports Q3 2024 Earnings: Revenue at $996,000, Non-GA - GuruFocus.com
Lucid Diagnostics Inc. (NASDAQ:LUCD) Q3 2024 Earnings Call Transcript - Insider Monkey
PAVmed Provides Business Update and Third Quarter 2024 Financial Results - Kilgore News Herald
Earnings call: Lucid Diagnostics reports revenue growth and strategic expansion - Investing.com UK
Lucid Diagnostics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lucid Diagnostics Reports Q3 Revenue Growth and Strategic Expansion - TipRanks
PAVMPAVmed Inc. Latest Stock News & Market Updates - StockTitan
Needham maintains Buy rating on Lucid Diagnostics shares - Investing.com
Lucid Diagnostics Reports Revenue Growth and Secures Funding - TipRanks
Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results - Nasdaq
Lucid Diagnostics Announces Convertible Notes Exchange Initiative - TipRanks
Lucid Diagnostics (LUCD) Scheduled to Post Earnings on Wednesday - MarketBeat
Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication - BioSpace
Lucid's EsoGuard Cancer Test Hits 88% Sensitivity, Wins Major Journal Publication | PAVM Stock News - StockTitan
Lucid Diagnostics expands direct contracting for cancer testing - Investing.com
Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers - PR Newswire
Lucid Diagnostics Expands EsoGuard Testing, Lands Major Firefighter Contract | PAVM Stock News - StockTitan
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024 - GuruFocus.com
PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024 - Kilgore News Herald
Lucid Diagnostics (NASDAQ:LUCD) Trading 1.5% HigherShould You Buy? - MarketBeat
Lucid Diagnostics (NASDAQ:LUCD) Trading 1.5% Higher – Here’s What Happened - Defense World
An unusual mascot and a former Cincinnati Bengal fight esophageal cancer - MM+M Online
Lucid Diagnostics to Participate in Upcoming Investor Conferences - GuruFocus.com
Lucid Diagnostics gets notice of allowance for patent underlying its esoguard esophageal DNA test - MSN
Lucid Diagnostics secures US patent for esophageal cancer test - Investing.com
Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test - StreetInsider.com
Lucid Diagnostics stock maintains Buy rating from BTIG - Investing.com India
Lucid Diagnostics stock maintains Buy rating from BTIG By Investing.com - Investing.com South Africa
Lucid Diagnostics Holds Inaugural #CheckYourFoodTube Precancer Testing Event for Former NFL Players - Aktiellt
PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care - StockTitan
October's 4 Best Penny Stocks: High-Risk, High-Reward Picks - Benzinga
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit - PR Newswire
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit | LUCD Stock News - StockTitan
Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024 - StreetInsider.com
Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024 – Company Announcement - Financial Times
Contrasting enVVeno Medical (NASDAQ:NVNO) and Lucid Diagnostics (NASDAQ:LUCD) - Defense World
Lucid Diagnostics Inc. (NASDAQ:LUCD) Position Trimmed by Nantahala Capital Management LLC - Defense World
Lucid Diagnostics' SWOT analysis: esophageal cancer screening stock faces pivotal year - Investing.com
Lucid Diagnostics Announces Multiple Presentations at the Upcomi - GuruFocus.com
Lucid Diagnostics Strengthens and Expands Market Access and Dire - GuruFocus.com
American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test - StockTitan
Lucid Diagnostics to be deconsolidated from PAVmed’s financial statements - Medical Buyer
Lucid Diagnostics to be deconsolidated from PAVmed's financial statements - Seeking Alpha
PAVmed moves to deconsolidate Lucid Diagnostics - Investing.com
PAVmed moves to deconsolidate Lucid Diagnostics By Investing.com - Investing.com UK
1.38%
0.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):